NEW YORK, April 2 - Gene Logic said Monday it had signed Sankyo, Japan’s second-largest pharmaceutical company, as a subscriber to its BioExpress and ToxExpress databases, bringing the total number of subscribers to 16.
Gene Logic did not disclose financial terms of the deal except to say that Sankyo had acquired the right to use the company’s databases and visualization tools throughout its research and development division.
The Gaithersburg, Md.-based database company has previously said that subscriptions to its individual databases such as BioExpress and ToxExpress generally go for $1.5 million a year and terms are usually for three years.
Sankyo said it would use the databases to search for new genes that could be used to develop new treatments.
"Our goal is to identify novel genes that have the potential to lead to innovative new compounds for the treatment of major diseases and disorders throughout the world. We believe Gene Logic's GeneExpress Suite can help to accelerate the process of identifying new genes for pharmaceutical development,” Sankyo said in a statement.
Gene Logic’s BioExpress database contains gene expression data on normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines for use in target identification and target validation studies. ToxExpress is a reference library of toxicity markers derived from examination of known toxic compounds in rodent model systems and across human and rat primary cell lines.
Amersham Pharmacia Biotech is Gene Logic’s sales and marketing partner in Japan.